The government today exempted Tamiflu, drug used for the treatment of H1N1 Influenza (swine flu) from customs duty allowing duty free import of 10 lakh capsules of the medicine.
Tamiflu, a patented drug of Swiss pharmaceutical major Roche, is the only available medicine against H1N1 influenza known as swine flu.
According to an official statement, Roche India has been allowed to import 10 lakh capsule of Tamiflu 75 mg (Oseltamivir Phosphate).
"As part of the effort to create a buffer stock of the drug, Oseltamivir Phosphate, used for the treatment of H1N1 influenza, government has decided that the drug would be imported by Roche India to supplement the stock manufactured in India," an official statement said.
The Central Board of Excise and Customs has issued an exemption order for duty free import of one million capsules of Tamiflu in 75 mg strength, it said.
The duty exemption order has been issued on the recommendation of the Department of Health and Family Welfare.
The government has earlier said that it would maintained a stock pile of three million capsules of the drug and has already placed orders for the purchase.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
